유바이오로직스

206650KOSDAQ

65.0 / 100

Reference Date: 2026-10-23

Financial Score34.5 / 40

News Sentiment12.5 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health and PER is significantly undervalued vs. peers is also solid. Declined 10.5% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

YuBioLogics, established in 2010, is a biotech company specializing in vaccine development and supply, as well as CRMO services. It supplies cholera vaccines to UNICEF, achieving sales of 65.4 billion KRW in 2023, with continued growth driven by increasing global cholera outbreaks. The company aims to expand its product line to include typhoid and meningitis vaccines, targeting global market leadership.

Number of Employees

397people

Average Salary

60.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

6.65Industry Average 15.008.0Point

Half of industry avg (excellent)

PBR

1.55Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE

26.85Industry Average 8.007.0Point

3.4x industry avg (excellent)

Debt Ratio

13.20Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20259.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲46.9% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲211.3% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 9.7% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (1%, downtrend)

Current 7,500Won52-week high 16,20052-week low 7,390

1-month return1.0Point

1m -10.50% (falling)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral투자판단관련주요경영사항(임상시험계획승인신청) (대상포진 예방 백신 EuHZV(유에이치지브이)주의 제2상 임상시험계획승인 신청(IND))2026-10-21
Neutral투자판단관련주요경영사항(임상시험결과) (대상포진 예방 백신 EuHZV(유에이치지브이)주의 제1상 국내 임상시험 결과)2026-10-21
Neutral본점소재지변경2026-10-06